FDA approves Adcirca tablets
SILVER SPRING, Md. The Food and Drug Administration has approved a new drug for the treatment of pulmonary arterial hypertension.
United Therapeutics Corp. announced Tuesday the approval of Adcirca (tadalafil) tablets, designed to improve exercise ability in WHO Group I PAH patients. The active ingredient is the same as the one in Eli Lilly & Co.’s Cialis, which is used to treat erectile dysfunction. United Therapeutics licensed the rights to develop and market Adcirca in the United States from Lilly.
“Today, thanks to the clinical development efforts led by Eli Lilly & Co., we are thrilled to make available an effective, convenient and economical therapy for PAH patients,” United Therapeutics chairman and CEO Martine Rothblatt said.
Aurora Health Care to sponsor run/walk for cancer
GREEN BAY, Wis. A nonprofit healthcare organization that operates hospitals, clinics and retail pharmacies in eastern Wisconsin will sponsor a run and walk to raise money for cancer.
Aurora Health Care announced Thursday that it would sponsor the Aurora Run/Walk for Cancer in Green Bay, Wis., on June 7, National Cancer Survivor’s Day. Proceeds from the event will benefit Aurora’s Vince Lombardi Cancer Clinics.
“The Aurora Run/Walk for Cancer provides cancer survivors and their support teams the opportunity to celebrate survivorship and reflect on what they’ve accomplished,” Vince Lombardi Cancer Clinic at Aurora BayCare Medical Center oncologist Dhimant Patel said. “While many appreciate being alive each and every day, this is a once-a-year opportunity to truly celebrate beating and living with cancer.”
Ranbaxy acquires dermatological and lifestyle product range of Ochoa Labs
GURGAON, India Indian drug maker Ranbaxy announced Thursday that it had acquired the trademarks, marketing rights and product dossiers for the entire dermatological and lifestyle product range of New Delhi-based Ochoa Labs.
Ranbaxy said the products commanded “considerable equity” with doctors, and it will initially market them in India, though it did not name specific products acquired.
“The move strengthens Ranbaxy’s domestic presence and market share in dermatology, a high-growth therapeutic segment for the company,” Ranbaxy chairman and CEO Malvinder Mohan Singh said. “I believe the Indian pharmaceutical space is ripe for consolidation, and Ranbaxy’s intent is to accelerate this trend with a view to reach commanding positions, especially in the high-value chronic and acute therapy areas.”